Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.


Onal C., Kose F., Ozyigit G., Aksoy S., Oymak E., Muallaoglu S., ...More

The Prostate, vol.81, pp.543-552, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 81
  • Publication Date: 2021
  • Doi Number: 10.1002/pros.24132
  • Title of Journal : The Prostate
  • Page Numbers: pp.543-552
  • Keywords: abiraterone, enzalutamide, oligometastasis, prostate cancer, stereotactic radiotherapy, MITOXANTRONE PLUS PREDNISONE, ABIRATERONE ACETATE, INCREASED SURVIVAL, RADIATION-THERAPY, DOUBLE-BLIND, ENZALUTAMIDE, DOCETAXEL, PROGRESSION, CHEMOTHERAPY, DECLINE

Abstract

Background Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA) treatment. We evaluated prognostic factors for prostate cancer-specific survival (PCSS) and progression-free survival (PFS) to characterize patients receiving treatment with ARTA who may benefit from MDT for oligoprogressive lesions. The impact of MDT on delaying NEST and the predictive factors for NEST-free survival (NEST-FS) were also assessed.